Aclaris Therapeutics shares jump 12.61% intraday on positive Phase 2a trial results for ATI-2138 and strong cash runway into 2028.

Aclaris Therapeutics surged 12.61% intraday after reporting better-than-expected Q3 2025 financial results and positive clinical data. The company’s Phase 2a trial of ITK/JAK3 inhibitor ATI-2138 showed significant improvements in atopic dermatitis metrics (EASI -77%, BSA -64%, PP-NRS -45%), validating its therapeutic target and supporting plans for a Phase 2 trial in a new indication by H1 2026. Revenue of $3.3 million exceeded estimates by 107.75%, while cash reserves of $167.2 million provided a runway through mid-2028, reducing near-term dilution risks. The EPS loss of $0.12, $0.01 above expectations, and disciplined R&D spending further reinforced operational progress. These milestones, including near-term clinical readouts and a strengthened balance sheet, drove investor optimism about de-risking the pipeline and long-term execution.